Pharmaceutical interventions in patients with Covid-19 in the Intensive Care Unit: A retrospective cohort

Resumo

Objectives: to describe the role of the clinical pharmacist, patient profile, medications, exams, death rate and length of stay in patients admitted to the intensive care unit (ICU) due to Covid-19. Methods: non-compared retrospective cohort study of adult patients ad-mitted to the Covid-19 ICU from six months. Data on dose, frequency and treatment time of the following classes of medications were collected: antimicrobials, corticosteroids, anticoagulants, colchicine, ivermectin and neuromuscular blockers. And, exam results: creatinine, D-dimers, ALT (alanine aminotransferase), AST (aspartate aminotransferase) and bilirubin. As well as the reason, quantity and outcome of the pharmaceutical inter-ventions carried out. Data refer to the first 15 days of hospitalization and were collected from the electronic medical record, Scola® laboratory exam portal and the NoHarm® artificial intelligence system. Results: 174 patients were included, the average age was 61.8 ± 14.1 years, length of stay was 17.3 ± 14.4 days, male (58.0%), with previous comorbidities (95, 4%), using mechanical ventilation (75.4%) and a mortality rate of 58.0%. Antimicrobials were the most used followed by corticosteroids and anticoagulan-ts. Age, use of mechanical ventilation, indication of anticoagulants, changes in creatinine and ALT were associated with death. One pharmaceutical intervention was carried out for every 13.1 prescriptions evaluated, with an acceptance rate of 86.8%. Conclusions: Pharmaceutical interventions and their outcomes showed the importance of the pharma-cist in the care of Covid-19 patients together with the multidisciplinary team.